Cite
Outcomes with ibrutinib by line of therapy in patients with CLL: Analyses from phase III data
MLA
Paul M. Barr, et al. “Outcomes with Ibrutinib by Line of Therapy in Patients with CLL: Analyses from Phase III Data.” Journal of Clinical Oncology, vol. 34, May 2016, p. 7520. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........a0960342d2841da0f1854c6abbce0216&authtype=sso&custid=ns315887.
APA
Paul M. Barr, Susan O’Brien, John C. Byrd, Jan A. Burger, Joi Ninomoto, Steven Coutre, Jennifer R. Brown, Tadeusz Robak, Jacqueline C. Barrientos, Danelle F. James, Alessandra Tedeschi, Peter Hillmen, Stephen Devereux, Stephen Chang, Nishitha Reddy, Thomas J. Kipps, Florence Cymbalista, & Paolo Ghia. (2016). Outcomes with ibrutinib by line of therapy in patients with CLL: Analyses from phase III data. Journal of Clinical Oncology, 34, 7520.
Chicago
Paul M. Barr, Susan O’Brien, John C. Byrd, Jan A. Burger, Joi Ninomoto, Steven Coutre, Jennifer R. Brown, et al. 2016. “Outcomes with Ibrutinib by Line of Therapy in Patients with CLL: Analyses from Phase III Data.” Journal of Clinical Oncology 34 (May): 7520. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........a0960342d2841da0f1854c6abbce0216&authtype=sso&custid=ns315887.